Glucagon

Glucagon

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Strong

At a Glance

A native 29-amino-acid hormone with product-specific labeled glucagon uses.

Plain English

Glucagon product details vary by formulation and label; they should not be transferred between products.

Overview

A native 29-amino-acid counter-regulatory hormone. Product-specific glucagon information must remain tied to the relevant labeled product: BAQSIMI nasal powder, GVOKE/GVOKE VialDx injection, or GlucaGen for injection.

Research Summary

BAQSIMI is a 3 mg one-actuation intranasal severe-hypoglycemia product for adults and pediatric patients age 1 year and older. GVOKE and GVOKE VialDx have distinct labeled routes and uses. GlucaGen has rescue and label-supported diagnostic GI-relaxation uses. Product-specific administration, safety, contraindications, storage, and age rules are not interchangeable.

Research Areas

  • Severe hypoglycemia reversal
  • Dual/triple incretin agonist design
  • Hepatic glucose metabolism
  • Energy expenditure
  • Cardioprotection research

Safety & Risks

Serious Risks

  • Hypoglycemia rebound after initial hyperglycemic response
  • Ineffective in depleted hepatic glycogen states (e.g., fasting, alcoholism)
  • Allergic reactions (rare)
  • Not a substitute for IV glucose in prolonged hypoglycemia

Reported Side Effects

  • Nausea
  • Vomiting
  • Headache
  • Injection site redness
  • Hyperglycemia (secondary rebound)
United States
FDA-approved prescription drug
United Kingdom
MHRA-approved
Australia
TGA-approved
Canada
Health Canada-approved

Citations & Sources